Clinical Trial Update: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating lenalidomide and dexamethasone with or without elotuzumab in newly diagnosed, untreated multiple myeloma; trial terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2021-07-01